Leukemia

Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.

Consolidative hematopoietic cell transplantation also confers improved progression-free survival among those with relapsed/refractory B-ALL.

Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

In a multicenter study, researchers have a phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating adults with relapsed/refractory AML.

A SEER-Medicare database analysis of patients with AML illustrates a trade-off between survival outcomes and time spent in hospitals.

Genomic subtype was associated with relapse, occurring in nearly 50% of PAX5-altered pediatric acute lymphoblastic leukemia cases.

Earlier use of liso-cel may improve responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.

Phase 1/2 data support the fast track designation for BGB-16673 as a therapy for patients with relapsed/refractory chronic lymphocytic leukemia.

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.

Phase 1/2 AUGMENT-101 study results revealed quick and lasting responses for patients with relapsed/refractory KMT2Ar acute leukemia.

The FDA has advised developers to attain overall survival benefit in a randomized head-to-head trial to support a BLA filing for Iomab-B.

An overall survival and 3-year relapse-free survival advantage was seen with blinatumomab vs chemotherapy alone in a phase 3 trial of B-cell precursor subtype ALL.

Investigators assessed alemtuzumab plus UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia as part of the phase 1 BALLI-01 trial.

Data from ASC4FIRST support the priority review designation for asciminib in Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Data from AMPLIFY show a trend towards improved overall survival with acalabrutinib-based therapy among patients with chronic lymphocytic leukemia.

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

A serious grade 4 adverse effect reported in the phase 1/2 dose-escalation study evaluating seclidemstat combination therapy prompted the partial hold.

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.

A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.

Four trajectories of change were identified in FACT-PWB score, with large patient groups experiencing little to no change or slight declines in PWB.

Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.

Phase 3 data from the E1910 trial support the FDA approval of blinatumomab in CD19-positive Philadelphia chromosome–negative B-cell precursor ALL.

Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.

Phase 1b data on SL-172154 in acute myeloid leukemia will be presented at the 2024 European Hematology Association Congress.

Toxicity in this phase 3 trial was comparable with prior reports of chemotherapy among patients with relapsed/refractory acute myeloid leukemia.